In C. elegans, the Ras and Wnt signaling pathways cooperate to specify vulval and P12 cell fates in a Hox-dependent manner. We have shown that mutations in
eor-1 or
eor-2 suppress mutations that activate the Ras and Wnt pathways. Since Ras pathway mutations do not suppress activated Wnt pathway mutations and since
eor-1 or
eor-2 mutations cause lethal phenotypes not associated with Wnt pathway mutations, we hypothesize that
eor-1 and
eor-2 do not act solely downstream of the Ras pathway or the Wnt pathway. Instead, we favor a model where
eor-1 and
eor-2 act at a convergence of the two pathways.
eor-1 encodes a nuclear-localized BTB/zinc-finger protein similar to the human transcription factor PLZF, which is altered in acute promyelocytic leukemia.
eor-2 encodes a novel nuclear-localized protein that functions closely with
eor-1. Because
eor-1 and
eor-2 act downstream of the Ras and Wnt pathways where transcription factors function and because of the molecular identity of EOR-1, it seems likely that EOR-1 and EOR-2 act at the level of transcriptional regulation. They could act as transcriptional repressors, like PLZF, or they could act as transcriptional activators. To distinguish between these two models, I have made fusions between the zinc-finger domains of EOR-1 and the Engrailed repressor domain and the VP16 activation domain and will test the ability of the fusion proteins to cause a phenotype in worms. I am also looking at expression of EGL-5 Hox and NOB-1 Hox in
eor-1 mutants to determine if Hox genes could be targets of EOR-1. The results of these experiments will be presented.